Wu Yilong is a leading figure in targeted therapy for lung cancer in China, who took the lead in compiling the guidelines for diagnosis and treatment of lung cancer in China, established the China lung cancer clinical trial cooperation organization, promoted the application of molecular targeted therapy, and firmly implemented the single-disease multidisciplinary management and individualized treatment measures for lung cancer. Wu Yilong is the first in China to put forward the characteristics of gene variation in patients with lung cancer, and is the first to jointly carry out clinical research with international counterparts, making targeted therapy for lung cancer in China one of the most important research forces in the world.

The chief expert system of single tumor disease was put forward for the first time in China, and the first truly multidisciplinary comprehensive treatment department of lung cancer was established. He took the lead in introducing evidence-based medicine into the field of cancer and became an academic leader in this field. At the 9th World Lung Cancer Congress held in Tokyo in 2000, he was awarded the "Researcher Award for Developing Countries". In 2002, the Knowledge of Diagnosis and Treatment of Locally Advanced (Stage Ⅲ) Non-small Cell Lung Cancer and the National Guidelines for Diagnosis and Treatment of Lung Cancer drafted by the Ministry of Health have become the standard reference books for diagnosis and treatment of lung cancer in China. In recent years, he has been invited to give speeches at international academic conferences many times.

At present, the first person in charge undertakes 6 scientific research projects-1 national key projects, 4 provincial and ministerial projects, and the Municipal Science and Technology Bureau1key scientific and technological projects. Seven awards * * *-three at the provincial and ministerial levels and four at universities. He has published more than 200 academic papers in core journals at home and abroad, including 80 international academic papers collected by SCI, EI and Mediline, and more than 70 academic papers published by the first author in Chinese and chinese magazine. Editor-in-chief of monographs "Theory and Practice of Multidisciplinary Comprehensive Treatment of Lung Cancer" and "Modern Lung Cancer Pathology and Clinic".

In 2004, he won the first "China Doctor Award".

In 2005, he was elected as an academician of American College of Surgery.